Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
oral paclitaxel + pertuzumab + trastuzumab
- Development stage
- Unknown
- Lead developer
- Daehwa Pharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Subcutaneous
01
Overview
This drug entry refers to a specific neoadjuvant combination regimen being evaluated in the OPTIMAL-BC clinical trial. The regimen consists of **Liporaxel** (an oral solution of paclitaxel) administered alongside a fixed-dose combination of the HER2-targeted monoclonal antibodies **pertuzumab** and **trastuzumab** for subcutaneous injection. Liporaxel, developed by Daehwa Pharmaceutical, is a lipid-based oral formulation of the microtubule stabilizer paclitaxel designed to improve patient convenience and eliminate the need for Cremophor EL, which is associated with hypersensitivity reactions in intravenous formulations. Pertuzumab and trastuzumab are monoclonal antibodies that bind to different domains of the Human Epidermal Growth Factor Receptor 2 (HER2), providing a dual blockade that synergistically inhibits HER2-mediated signaling and promotes antibody-dependent cellular cytotoxicity (ADCC). This combination is specifically being studied for the neoadjuvant treatment of HER2-positive breast cancer.
- Brand names
- LiporaxelPhesgo
- Other names
- OPTIMAL-BC regimenoral paclitaxel plus fixed-dose combination of pertuzumab and trastuzumab
02
Targets
TUBB (Tubulin (alpha and beta subunits))ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on oral paclitaxel + pertuzumab + trastuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on oral paclitaxel + pertuzumab + trastuzumab.